cabergoline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
ergot alkaloid derivatives 460 81409-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cabergoline
  • dostinex
  • galastop
  • cabaser
  • cabaseril
An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.
  • Molecular weight: 451.62
  • Formula: C26H37N5O2
  • CLOGP: 4.17
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 71.68
  • ALOGS: -3.85
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg O
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1996 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aortic valve incompetence 345.59 37.57 55 695 840 2356495
Mitral valve incompetence 214.30 37.57 43 707 2507 2354828
Tricuspid valve incompetence 115.67 37.57 24 726 1632 2355703
Parkinson's disease 103.03 37.57 21 729 1305 2356030
Cardiac valve disease 102.71 37.57 19 731 707 2356628
Abortion spontaneous 97.07 37.57 32 718 13413 2343922
Blood prolactin increased 95.41 37.57 19 731 1048 2356287
Exposure during pregnancy 74.04 37.57 31 719 25188 2332147
Hallucination 73.49 37.57 23 727 8125 2349210
Condition aggravated 70.12 37.57 32 718 31947 2325388
Aortic valve sclerosis 68.54 37.57 11 739 172 2357163
Mitral valve disease 67.32 37.57 12 738 360 2356975
Gambling disorder 64.94 37.57 11 739 243 2357092
Pleural effusion 57.80 37.57 21 729 11647 2345688
Mastitis 51.33 37.57 10 740 489 2356846
Drug interaction 48.00 37.57 24 726 29139 2328196
Prolactin-producing pituitary tumour 46.96 37.57 7 743 65 2357270
Pregnancy 45.74 37.57 16 734 7933 2349402
Headache 45.00 37.57 33 717 80146 2277189
Dyspnoea 43.26 37.57 32 718 78701 2278634
Caesarean section 43.00 37.57 13 737 4068 2353267
Delusion 41.97 37.57 11 739 2054 2355281
Pneumocephalus 40.83 37.57 6 744 50 2357285
Pulmonary hypertension 40.10 37.57 13 737 5105 2352230

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aortic valve incompetence 238.66 47.34 40 494 720 1745527
Mitral valve incompetence 189.11 47.34 38 496 1904 1744343
Gambling disorder 181.28 47.34 29 505 381 1745866
Pleural effusion 140.55 47.34 42 492 11068 1735179
Tricuspid valve incompetence 112.79 47.34 23 511 1223 1745024
Cerebrospinal fluid leakage 96.02 47.34 15 519 165 1746082
Cardiac valve disease 91.08 47.34 17 517 564 1745683
Aortic valve sclerosis 89.94 47.34 14 520 150 1746097
Cardiac failure 78.70 47.34 28 506 12574 1733673
Pleural fibrosis 77.65 47.34 13 521 226 1746021
Hallucination 73.94 47.34 24 510 8146 1738101
Pleurisy 60.49 47.34 13 521 884 1745363
Oedema peripheral 52.07 47.34 22 512 15528 1730719
Parkinson's disease 51.90 47.34 13 521 1729 1744518
Intracranial hypotension 48.26 47.34 8 526 130 1746117

Pharmacologic Action:

SourceCodeDescription
ATC G02CB03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Prolactine inhibitors
ATC N04BC06 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA Chemical/Ingredient N0000007618 Ergolines
FDA EPC N0000175827 Ergot Derivative
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:51065 dopamine agonist
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:35610 antineoplastic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hyperprolactinemia indication 237662005 DOID:12700
Heart valve disorder contraindication 368009 DOID:4079
Severe pre-eclampsia contraindication 46764007
Retroperitoneal fibrosis contraindication 49120005
Fibrosis of lung contraindication 51615001 DOID:3770
Fibrosis of pericardium contraindication 194965002
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Hypertensive urgency contraindication 443482000
Occlusive Vascular Disease contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.83 acidic
pKa2 13.48 acidic
pKa3 7.88 Basic
pKa4 5.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 9.20 IUPHAR CHEMBL
D(3) dopamine receptor GPCR AGONIST Ki 9.10 IUPHAR
5-hydroxytryptamine receptor 2A GPCR AGONIST Ki 8.20 IUPHAR
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.10 IUPHAR
Alpha-2A adrenergic receptor GPCR ANTAGONIST Ki 7.90 IUPHAR
D(1B) dopamine receptor GPCR AGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 7.70 IUPHAR
Alpha-2C adrenergic receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
D(4) dopamine receptor GPCR AGONIST Ki 7.30 IUPHAR
Alpha-2B adrenergic receptor GPCR ANTAGONIST Ki 7.10 IUPHAR
D(1A) dopamine receptor GPCR AGONIST Ki 6.70 IUPHAR
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 6.50 IUPHAR
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.30 IUPHAR
5-hydroxytryptamine receptor 2C GPCR AGONIST Ki 6.20 IUPHAR
Alpha-1D adrenergic receptor GPCR Ki 6.78 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.22 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 8.85 CHEMBL

External reference:

IDSource
D000077465 MESH_DESCRIPTOR_UI
4021014 VUID
N0000148483 NUI
C0107994 UMLSCUI
D00987 KEGG_DRUG
109139002 SNOMEDCT_US
4021014 VANDF
73532 MMSL
005446 NDDF
d04112 MMSL
4317 MMSL
47579 RXNORM
386979007 SNOMEDCT_US
DB00248 DRUGBANK_ID
LL60K9J05T UNII
5860 INN_ID
CHEBI:3286 CHEBI
37 IUPHAR_LIGAND_ID
CHEMBL1201087 ChEMBL_ID
54746 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 0093-5420 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 49884-673 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3951 TABLET 0.50 mg ORAL ANDA 12 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50742-118 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 59762-1005 TABLET 0.50 mg ORAL NDA AUTHORIZED GENERIC 13 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 68071-4596 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 70518-2379 TABLET 0.50 mg ORAL ANDA 11 sections